For Immediate Release

January 30, 2015

Sumitomo Chemical Reports
Consolidated Financial Results
For the Nine Months Ended December 31, 2014
The Sumitomo Chemical Group’s sales for the nine months ended December 31, 2014,
were ¥1,723.0 billion, an increase of ¥116.7 billion compared with the same period of
the previous fiscal year. Operating income came to ¥71.4 billion, almost unchanged
from the same period of the previous fiscal year. The Group posted ordinary incomeof ¥98.7 billion and net income of ¥47.2 billion, both representing year-on-yearincreases.
The Sumitomo Chemical Group’s financial results by business segment for thenine-month period were as follows.
Basic Chemicals
Sales of methyl methacrylate grew due to an increase in shipments and higher
market prices. Sales of aluminum also rose due to higher market prices. Howevermarket prices remained low for raw materials for synthetic fibers and shipments ofthese products decreased. The weaker yen had a positive effect on sales fromoverseas subsidiaries in yen terms. As a result, the segment’s sales increased by¥25.2 billion from the same period of the previous fiscal year, to ¥230.4 billion.
Operating income improved by ¥5.0 billion, to a loss of ¥2.5 billion.
Petrochemicals & Plastics
Shipments of synthetic resins from overseas subsidiaries increased, while market
prices of petrochemical products and synthetic resins remained high. The weaker
yen had a positive effect on sales from overseas subsidiaries in yen terms. As aresult, the segment’s sales grew by ¥43.8 billion from the same period of the previous
fiscal year, to ¥615.2 billion, and operating income rose by ¥4.0 billion, to ¥9.5 billion.
IT-related Chemicals
Shipments of polarizing film used in liquid crystal displays (LCDs) increased due togrowth in demand, while selling prices of polarizing film declined. Although selling
prices of touchscreen panels declined, shipments grew because of increased
production capacity. The weaker yen had a positive effect on sales from overseas
subsidiaries in yen terms. As a result, the segment’s sales increased by ¥24.7 billion
compared with the same period of the previous fiscal year, to ¥298.2 billion.
Operating income decreased by ¥5.4 billion, to ¥23.8 billion, as it was adversely
affected by lower selling prices.
Health & Crop Sciences
Sales of the feed additive methionine grew due to a recovery in market prices and anincrease in shipments. In the area of crop protection chemicals, shipments
decreased in Japan due to the effects of the consumption tax increase, shipments
rose in overseas markets due to expanded sales. As a result, including the positiveeffect of the weaker yen, the segment’s sales increased by ¥23.8 billion comparedwith the same period of the previous fiscal year, to ¥231.0 billion, and operating
income grew by ¥8.2 billion, to ¥22.8 billion.

Pharmaceuticals
In North America, shipments of Lunesta® (sedative hypnotic) decreased sharply asmarketing exclusivity ended. Shipments of Latuda® (atypical antipsychotic), however,expanded significantly. In China, shipments of Meropen® (carbapenem antibiotic)
showed steady growth. In Japan, overall sales decreased sharply due to the impactsof Japanese National Health Insurance drug price revisions and competition fromgeneric drugs. As a result, the segment’s sales declined by ¥4.8 billion comparedwith the same period of the previous fiscal year, to ¥303.1 billion, and operating
income decreased by ¥11.6 billion, to ¥27.6 billion.
OthersIn addition to the above five segments, the Sumitomo Chemical Group engages insupplying electrical power and steam, providing services for the design, engineering,and construction management of chemical plants, providing transport andwarehousing, and conducting materials and environmental analysis. The segment’s
sales increased by ¥4.0 billion compared with the same period of the previous fiscalyear, to ¥45.0 billion. Operating income decreased by ¥0.2 billion, to ¥5.0 billion.

Summary of Consolidated Results(1) Results of Operations:

Net sales
Operating income
Ordinary income
Income before income taxes
and minority interests
Net income

Net income per 1,000 shares

Comprehensive income(2) Financial Position:
Total assets
Total net asset(3) Cash Flows:

Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations byBusiness Segment:
Net sales
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersOperating income (loss)
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

9 Months ended
December 31，2014
Yen (Millions)
USD (Thousands)*
1,722,957
14,292,468
71,360591,954
98,687
818,640

9 Months ended
December 31，2013
Yen (Millions)
1,606,250
71,161
72,643

99,97947,218829,357
391,688

63,082
24,553

Yen
28,889

USD*
240

Yen
15,021

Yen (Millions)
170,059

USD (Thousands)*
1,410,693

Yen (Millions)
148,654

As of December 31, 2014
Yen (Millions)
USD (Thousands)*
3,076,836
25,523,318
1,077,773
8,940,465

As of March 31, 2014
Yen (Millions)
2,788,507
934,506

9 Months ended
December 31，2014
Yen (Millions)
USD (Thousands)*(12,697)(105,326)(32,512)(269,697)
112,456
932,858
219,711
1,822,572

9 Months ended
December 31，2013
Yen (Millions)
93,991(124,376)
57,331
162,739

9 Months ended
December 31，2014
Yen (Millions)
USD (Thousands)*

9 Months ended
December 31，2013
Yen (Millions)230,429615,208
298,247
230,965
303,094
45,014
1,722,957

1,911,481
5,103,343
2,474,052
1,915,927
2,514,260
373,405
14,292,468

205,209571,424
273,529
207,178
307,938
40,972
1,606,250(2,521)
9,458
23,766
22,836
27,581
5,031(14,791)
71,360(20,912)78,457
197,146
189,432
228,793
41,734(122,696)
591,954(7,475)
5,415
29,18914,65339,2085,255(15,084)
71,161(Note)*:U.S. dollar amounts are translated from yen, for convenience only, at the rate of¥120.55= $1 prevailing on December 31, 2014.